



World class facilities, a strong industry cluster and a history of excellence in pharma and biomedical research are just three of the reasons why Medicon Valley, spanning Eastern Denmark and Skåne in southern Sweden, excels in the field of oncology. The region is known for its collaborative ecosystem that thrives using a triple helix approach. Universities, industry and public actors work together to support innovative advancements in oncology.

PROFESSIONAL ADVISORY SERVICES FREE OF CHARGE

Our advice and services are designed to help you find the right investment opportunities, the right business partners and the best location for your venture. We combine business intelligence and professional advisory services to match your company's specific needs.

FOR MORE INFORMATION PLEASE CONTACT:

Sweden

Ulrika Mårtensson
Business Development Manager
Invest in Skåne
ulrika.e.martensson@skane.com
+46 721 99 81 12

Denmark

Niels Thun Andersen
Business Development Manager
Copenhagen Capacity
nta@copcap.com
+45 30 62 74 27

A GLOBAL EPICENTER FOR ONCOLOGY RESEARCH

WELCOME TO GREATER COPENHAGEN AND SOUTHERN SWEDEN

invest in skåne

COPENHAGEN
CAPACITY
Invest in Greater Copenhagen

Interreg
Öresund-Kattegat-Skagerrak
European Regional Development Fund
EUROPEAN UNION

 **ESS & MAX IV:**
Cross Border
Science and Society

ONCOLOGY RESEARCH IN MEDICON VALLEY

→ MEDICON VALLEY AT A GLANCE

- 11 University hospitals (28 hospitals in total)
- 3 Global R&D pharmaceutical companies: Leo, Novo Nordisk, Lundbeck
- 350+ life science companies dedicated to R&D,
- 45 with specialized oncology R&D
- 14 000 researchers and 40 000 life science professionals working in the region
- Biobanks, among the most advanced and comprehensive in the world
- New world class research facilities MAX IV and ESS (European Spallation Source)

→ ADVANCED ACADEMIC RESEARCH

CREATE Health – a cross-disciplinary centre for clinical cancer research that studies cancer biology using genomics, proteomics and nanotechnology to develop novel cancer treatments and diagnostics.

MAD for Cancer – aiming to make a difference (MAD) in cancer research, by bringing together several facets of cancer biology into a multifocal approach. Areas include molecular diagnosis, patient stratification, targeted therapies, chemical and stromal biology, psychological resilience and cancer stem cells.

Danish Centre for Transnational Breast Cancer Research – represents a unique collaboration between basic researchers, clinicians and epidemiologist from five major research institutions.

Danish Cancer Society – an NGO that through research, prevention and patient support aims to minimize the number of people that develop cancer and increase survival rate amongst cancer patients.

→ CLINICAL TRIALS

Medicon Valley has a strong background in clinical research. Two main contributors to the success are the partnerships that are formed between industry, universities and healthcare organizations. A framework to secure compliance with regulations and ethical aspects are also key in securing the quality of the data provided.

- Phase 1 Unit at Rigshospitalet, Copenhagen – has a new unit dedicated to Phase I and II cancer research trials and recruits patients from Medicon Valley.
- Phase 1 Unit at Lund University Hospital – performs all types of clinical trials but focuses on Phase I and Phase II studies. Is approved by the Swedish Medical Product Agency to perform FIH studies.

The National Experimental Therapy Partnership (NEXT) – is a public-private partnership within clinical research consisting of the regions of Denmark, universities, twelve pharmaceutical companies and one GTS institute.

SCANDINAVIA'S LEADING LIFE SCIENCE REGION

→ INNOVATIVE ONCOLOGY COMPANIES IN MEDICON VALLEY

2CureX, Alligator Bioscience, Bavarian Nordic, Genmab, Diaprost, Bioinvent, Cantargia, Camurus

→ ADVANCED RESEARCH FACILITIES



MAX IV Laboratory

The most brilliant x-ray light source can be used in drug development:

- Imaging of living structures in extreme detail
- X-ray crystallography to study 3D protein structures of drug candidates
- Powder diffraction for new drug formulations

→ EXTENSIVE BIOBANKS

The Swedish and Danish governments have invested in building up national and regional biobanks and registers with extensive information about residents. In the same way the healthcare systems have routinely collected biological material from a large number of individuals. Some of our biobanks date back to the early 70s.



European Spallation Source (ESS)

Neutron scattering helps us see hydrogen atoms, which is valuable for investigating the structure and dynamics in biological systems of diseases.

- Biological macromolecules such as proteins or nucleic acids
- Macromolecular complexes and aggregates in solution
- Single biological membranes

The Danish National Biobank is one of the most advanced and comprehensive data registries in the world and has a registry with 22 million samples from 5,4 million people. The regional biobank for Skåne is one of six biobanks in Sweden and has a registry with 24,2 million samples.